Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma

Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma

礼来 CEO Dave Ricks 谈 GLP-1 药物与制药商业

Stripe11 位订阅者

151 分钟阅读Wall Street

【医药巨头】礼来 CEO 谈 GLP-1 革命:AI 正在如何缩短新药研发的“死区”? 除了减肥药的神话,礼来公司正在经历一场数字变革。Dave Ricks 详细拆解了 AI 在分子发现和临床试验模拟中的应用,这让原本长达 10 年的研发周期有了缩短一半的可能。这是一份关于生命科学与数据智能深度碰撞的行业报告。 🎙️ 访谈人物介绍 Dave Ricks:全球医药巨头礼来(Eli Lilly)董事长兼 CEO,主导了礼来在代谢疾病领域的革命性突破。 核心议题:GLP-1 的市场逻辑、AI 在新药筛选中的作用、数字医疗的终局、制药行业的增长悖论。 关键词:礼来、Dave Ricks、AI 医疗、GLP-1、制药创新

章节 1:百年巨头与完美的一品脱 (The 150-Year Giant & The Art of the Pour)

📝 本节摘要:

访谈在一种轻松的氛围中拉开序幕。Eli Lilly(礼来)的第11任CEO Dave Ricks以娴熟的手法为自己倒了一杯吉尼斯黑啤,这一举动被主持人风趣地称为“实力的炫耀(Major flex)”。开场旁白简要勾勒了礼来公司的行业地位:作为一家拥有150年历史、市值7000亿美元的制药巨头,它不仅是全球最有价值的制药公司,正凭借GLP-1药物引领市场,并通过LillyDirect直销模式颠覆传统的医药分销体系。

[原文] [Dave Ricks]: I'm the 11th CEO of the company. That's one less than popes in that period of time.

[译文] [Dave Ricks]: 我是这家公司的第11任CEO。在同一时期内,这个数量比教皇的人数还少一个。

[原文] [Host]: Where did you learn to pour?

[译文] [Host]: 你是在哪里学会倒酒的?

[原文] [Dave Ricks]: I actually learned in Ireland.

[译文] [Dave Ricks]: 我其实是在爱尔兰学的。

[原文] [Host]: Okay, do you want me to leave it down? You're the expert here.

[译文] [Host]: 好吧,你要我把它(杯子)放下吗?你才是这方面的专家。

[原文] [Dave Ricks]: Okay, oscillate this way.

[译文] [Dave Ricks]: 好的,让它这样回旋流动。

[原文] [Host]: That's an excellent pint.

[译文] [Host]: 这是一杯极好的啤酒。

[原文] [Dave Ricks]: Yeah.

[译文] [Dave Ricks]: 是的。

[原文] [Narrator]: Dave Ricks is CEO of Eli Lilly, which is now a $700 billion company and the world's most valuable pharma company. Eli Lilly is 150 years old. They grew up as the first company to mass produce insulin in the 20th century. But today most of the company's business is in the new GLP-1 diabetes and weight loss drugs where they've become the market leader. Simultaneously, Eli Lilly is upending the traditional model by selling directly to their consumers over the internet with LillyDirect rather than through the traditional middleman.

[译文] [旁白]: Dave Ricks是Eli Lilly(礼来公司)的CEO,该公司目前市值7000亿美元,是全球最有价值的制药公司。礼来公司已有150年的历史。他们在20世纪作为首家大规模生产胰岛素的公司而成长起来。但如今,该公司的主要业务集中在新型GLP-1糖尿病及减肥药物上,并在该领域成为了市场领导者。与此同时,礼来正在颠覆传统模式,通过LillyDirect在互联网上直接向消费者销售产品,而不是通过传统的中间商。

[原文] [Host]: All right, cheers.

[译文] [Host]: 好的,干杯。

[原文] [Dave Ricks]: Cheers.

[译文] [Dave Ricks]: 干杯。

[原文] [Host]: Cheers. Thanks for coming.

[译文] [Host]: 干杯。感谢你的到来。

[原文] [Dave Ricks]: Good to be here.

[译文] [Dave Ricks]: 很高兴来到这里。

[原文] [Host]: I'm very impressed that you came and you just poured your own pint.

[译文] [Host]: 我印象非常深刻,你来了并且亲自倒了自己的这杯酒。

[原文] [Dave Ricks]: Poured my own pint, yeah.

[译文] [Dave Ricks]: 倒了我自己的酒,是的。

[原文] [Host]: Major flex.

[译文] [Host]: 绝对是实力炫耀(Major flex)。

[原文] [Dave Ricks]: Have glass, will pour.

[译文] [Dave Ricks]: 只要有杯子,我就能倒。

[原文] [Host]: Exactly. Well, actually a good place to start.

[译文] [Host]: 没错。好吧,这其实是一个很好的开始。


(注:原文开头提及的“R&D投入对比德国”部分为视频预告片段,将在后续关于研发经济学的章节中完整呈现)

  1. 章节 2:AI超算与药物研发的“外星”化学 (AI Supercomputers & The "Alien" Chemistry)
  2. 章节 3:30亿美元的豪赌与科学决策 (The $3 Billion Bet & Scientific Decision Making)
  3. 章节 4:临床试验的经济账:4万美元一个病人? (The Economics of Clinical Trials: $40k Per Patient?)
  4. 章节 5:泰勒·斯威夫特效应与招募瓶颈 (The Taylor Swift Effect & The Enrollment Bottleneck)
  5. 章节 6:医学界的乔丹与监管的“单向棘轮” (The Michael Jordan of Medicine & The Regulatory Ratchet)
  6. 章节 7:为预防买单与打破“在位者”魔咒 (Paying for Prevention & The Incumbency Problem)
  7. 章节 8:进化的陷阱与“第二顿早餐” (The Evolutionary Trap & The "Second Breakfast")
  8. 章节 9:基因疗法的商业困局:SaaS模式与“一次性治愈” (The Business of Cures: SaaS vs. "One-and-Done")
  9. 章节 10:全球定价悖论与“总净差额”泡沫 (The Global Pricing Paradox & The "Gross-to-Net" Bubble)
  10. 章节 11:打破泡沫:自杀式降价与全球“搭便车” (Bursting the Bubble: The Insulin "Hack" & The Global Free Rider)
  11. 章节 12:“单一公平价格”提案与1.4万美元的赤霞珠 (The "One Fair Price" Proposal & The $14,000 Cabernet)
  12. 章节 13:恶意合规与650美元的抽血 (Malicious Compliance & The $650 Blood Draw)
  13. 章节 14:橡木地板诊所与“奇怪”的私营医疗 (Oak-Floored Clinics & The "Weird" Private Healthcare)
  14. 章节 15:治疗指数的非线性扩张与“去中介化”未来 (Non-Linear Expansion of Therapeutic Index & The Disintermediated Future)
  15. 章节 16:谁在驱动创新?生物科技 vs. 传统的“垂直整合” (Who Drives Innovation? Biotech vs. Traditional "Vertical Integration")
  16. 章节 17:中国阴影与生物科技的“安全警钟” (The "Shadow" of China & The Biotech Security Alarm)
  17. 章节 18:专利系统的漏洞与“影子仿制”产业 (The Loophole in Patents & The "Shadow Generic" Industry)
  18. 章节 19:离岸制造与“5%规则”的隐患 (Offshore Chemistry & The "5% Rule" Risk)
  19. 章节 20:希拉毒蜥与“肠促胰素”的魔法 (Gila Monsters & The "Incretin Effect")
  20. 章节 21:口服药的必然未来与广告的“必要之恶” (The Inevitable Oral Future & The "Necessary Evil" of Ads)
  21. 章节 22:灰色地带的“中国多肽”与LillyDirect的诞生 (The Grey Market of "Chinese Peptides" & The Birth of LillyDirect)
  22. 章节 23:全球药企市值之王:80法则与碾压诺和诺德 (The King of Pharma Valuation: Rule of 80 & Crushing Novo)
  23. 章节 24:50倍市盈率背后的“蓝海”逻辑与研发赌注 (The "Blue Ocean" of $0 Markets & The 25% R&D Gamble)
  24. 章节 25:平台与靶点的博弈 & 150年的“人才赌局” (Platform vs. Target & The 150-Year Talent Gamble)

正在加载后续章节…

更多 Wall Street

查看全部 →